Targeting ALT positive cancers
Our ALT (Alternative Lenghening of Telomeres) program is partnered with Boehringer Ingelheim under a research collaboration and global license agreement.
Alternative Lengthening of Telomeres (ALT)
In healthy cells, telomeres progressively shorten after each cell division, limiting the number of replications. Cancer cells overcome telomere shortening and thus the replication limitations. One of the mechanisms allowing unlimited proliferation is ALT.
ALT patient population – snapshot
ALT is an important survival mechanism in 10-15% of all cancers and is associated with poor prognosis and a lack of targeted therapies.
Each year, approximately 1 million patients die from ALT+ cancers.
ALT Companion Diagnostic (CDx)
Diagnostic development starts at early stages of our drug discovery programs
Tessellate Bio is validating and developing a companion diagnostic (CDx) for our ALT program. The CDx determines ALT status by detecting C-Circles, which are recognized as the best biomarker for ALT+ cancers.